Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A training network on glyconanomaterials as precision tools to unveil key insights on the triggering of the antigen presenting cells against cancer

Project description

Training in glyconanotechnology to fill gaps in cancer immunotherapy

Cancer immunotherapy is a rapidly advancing therapeutic approach, with vaccine prototypes in phase III trials. However, guidelines to select the optimal format (mRNA vs peptide) in vaccine formulations are urgently needed for clinical translation. Glyconanomaterials can address this challenging task providing the precision delivery antigens to antigen-presenting cells (APC) and boosting APC activation. With the support of the Marie Skłodowska-Curie Actions programme, the CanGoNano project will explore glyconanotechnology to shed light on the molecular mechanisms of immune system activation, leading one step closer to the development of cancer vaccines. It will train doctoral candidates in the synergistic potential of glycoscience and nanotechnology to fill knowledge gaps in cancer immunotherapy, equipping them with valuable skills for careers in academia and industry.

Objective

Immunotherapy is at the frontier of cancer treatment, with vaccine prototypes in phase III clinical trials. However, guidelines for the selection of the optimal antigen format (mRNA vs peptide) to be used in vaccine formulations are still not available. The glycoscience-oriented CanGoNano DN has identified this gap and proposes for the first time a research & training & innovation action that aims to unveil the molecular mechanisms of immune system activation at the molecular level. Our innovative DN puts antigen presenting cells (APC) as the immune system hub to move forward on the rational selection of antigen formats towards next generation of cancer vaccines. Glyconanomaterials are precision tools for the controlled delivery of antigens to APC and will shed light on molecular mechanisms that rule APC activation according to antigen format. CanGoNano credibility and high quality are ensured by a partnership of experts in glycoscience & nanotechnology & immunology. 12 Academics, 6 SMEs & 1 clinical Institution encompass complementary & intersectoral expertise, and unique tools to train 14 doctoral candidates (DC). The combination of interdisciplinary & excellent science, industry know-how and clinical perspective will cover the entire process from fundamental insights to innovative solutions. CanGoNano will create a critical mass of uniquely skilled researchers in glyconanotechnology. We will train DC on the synergic potential of glycoscience & nanotech to provide the missing knowledge in cancer immunotherapy, and will equip DC with transferrable skills to be in an advantageous position for job opportunities in academia and industry. Deciphering the key interactions in APC activation expands the frontiers of knowledge and enables addressing key challenges in cancer immunotherapy. CanGoNano will strengthen the EU innovation capacity bringing new fundamental knowledge for the future development of precision anticancer vaccines to market and policy stakeholders.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-DN-01

See all projects funded under this call

Coordinator

UNIVERSITA DEGLI STUDI DI FIRENZE
Net EU contribution
€ 845 265,24
Address
Piazza San Marco 4
50121 Florence
Italy
Region
Centro (IT) Toscana Firenze
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (10)

Partners (11)